Australian researchers have been at the fore of the largest genetic study of glaucoma that has identified 44 new genetic variants that may lead to new treatment targets. Read more
Public MIGS funding a step closer for iTrack in Australia
Nova Eye Medical has announced an application to secure public funding for its iTrack ab-interno canaloplasty as a standalone minimally invasive glaucoma surgery (MIGS) procedure in Australia has formally progressing to the third and final stage of the assessment process. Read more
New myopia alliance to overcome axial length challenge
Unprecedented clinical interest in measuring axial length has fuelled a new partnership between the world’s largest multi-platform digital suite for myopia management and an optical device company headquartered in Germany. Read more
Australia trial commences for ‘game-changer’ retinal disease eye drop
A clinical trial is under way in Australia for a novel eye drop treatment for retinal vascular diseases that could replace the current approach involving serial intravitreal injections into the back of the eye. Read more
CooperVision and Essilor announce JV for acquisition of myopia spectacle lens
The parent companies of CooperVision and Essilor have announced a new joint venture to acquire a spectacle lens approved for myopia control in several countries. Read more
Low carb diet an antidote to type 2 diabetes?
An Australian researcher has contributed to a new study demonstrating that lower carbohydrate consumption can potentially put type 2 diabetes into remission. Read more
Presbyopia eye drop in final stage of clinical development
An ophthalmic pharmaceutical company has commenced two Phase 3 clinical studies to evaluate its eye drop candidate for presbyopia. Read more
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more
MBS Taskforce keeps controversial eye injection proposals in final report
Despite vehement opposition from ophthalmologists, the MBS Taskforce has forged ahead with plans to cut the rebate for intravitreal injections and consider allowing nurses and optometrists to perform the procedure in its final report to the Federal Government. Read more
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). Read more